Flush From Roche Deal, Epigenomics Readies Methylation Kit for Research | GenomeWeb

Epigenomics will soon begin selling a kit to US-based research labs that will enable them to interpret DNA methylation states in a variety of cancers, a company official told SNPtech Reporter this week.

The German tool shop hopes the offering will help validate its methylation technology as an effective platform not only as a key component in molecular diagnostics — thanks to a recent deal with Roche Diagnostics — but also as a staple among researchers comparing diseased tissue against normal tissue.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.